They concluded that there was a dose-dependent relationship between all causes of dying and shorter telomeres. The “p-value” is the estimate that this relationship was due to random chance. That p-value was 0.000000000000002 or 2 in 1,000,000,000,000,000 odds.
cells from prostate cancer patients with short telomeres and hypervariable lengths were 14X more likely to die of their disease
Anderson et al showed a significant association with shorter telomeres and risk of dementia and mortality. But they call for more research and decline to state the two are causally related.
DISCLAIMER: This website is for educational purposes only and is not for advertising. Telomerase activators and nanovesicles are not FDA-approved to prevent or treat any disease and anecdotes are not scientific proof of efficacy. All patients were treated in the context of a fully informed and legally-protected patient physician relationship.
Required fields
© 2020 Recharge Biomedical
Exosomes and TA-65 are not FDA-approved to prevent or treat any illness
